Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 99

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 99
---
 of common stock subject to outstanding RSUs under the 2023 Stock Incentive Plan, or the 183,000 shares of common stock subject to outstanding PSUs under the 2023 Stock Incentive Plan. RSUs and PSUs do not have an exercise price. Such shares will be issued at the time such awards vest, without any cash consideration payable for those shares. |

| (3) | Represents inducement awards granted to Mr. Goff, Ms. Jones and Ms. Milanova during 2022 and 2023 outside of our equity incentive plans, as inducements material to Mr. Goff’s, Ms. Jones’ and Ms. Milanova’s entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). These awards consist of (i) an option to purchase 561,083 shares of common stock at an exercise price of $29.38 per share granted to Mr. Goff, an option to purchase 118,390 shares of common stock at an exercise price of $27.88 per share granted to Ms. Jones, and an option to purchase 135,682 shares of common stock at an exercise price of $27.53 per share granted to Ms. Milanova, which options shall vest as to 25% of the underlying shares on the one year anniversary of the respective dates of grant and as to the remaining shares on a monthly basis thereafter, of which all options were all outstanding as of December 31, 2024; (ii) grants of RSUs, an aggregate of which 47,144 were outstanding as of December 31, 2024 and (iii) grants of PSUs an aggregate of which 76,853 were outstanding as of December 31, 2024. For more information about the awards, see “Executive Compensation” above. |

| (4) | This calculation does not take into account the 47,114 shares subject to RSUs or the 76,583 shares subject to PSUs granted as inducement awards that were outstanding as of December 31, 2024. RSUs and PSUs do not have an exercise price. Such shares will be issued at the time such awards vest, without any cash consideration payable for those shares. |

78

Compensation Committee Interlocks and Insider Participation For 2024, the membersof our compensation & peoplecommittee were Ms. Smith (chair), Ms. Owen and Ms. Foster, none of whom is, or ever has